The Zetia controversy and New Year's resolutions will spark new emphasis on treating lipids

January 2010

The Zetia controversy and New Year's resolutions will spark new emphasis on treating lipids...especially when combo therapy is needed.

We know statins are first-line for lowering LDL and cardiac risk.

But they don't always get patients to their lipid goals. And experts differ about what to do when a statin isn't enough.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

Cutting-edge advice about new medications and how they fit into practice
Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote